| MTX-use |
p
| CV-Event |
p
|
---|
Yes (n = 222) | No (n = 163) | Yes (n = 23) | No (n = 362) |
---|
RDW, mean(SD), % | 14,5 (1,4) | 14,1 (1,6) | < 0,001 | 15,05 (2,2) | 14,25 (1,4) | 0,116 |
Hb, mean(SD), g/l | 134,8 (14,5) | 132,9 (14) | 0,101 | 130,2 (14,4) | 134,2 (14,3) | 0,058 |
CRP, mean(SD), mg/dl | 0,65 (0,97) | 1,03 (2,1) | 0,559 | 0,99 (1,1) | 0,8 (1,6) | 0,060 |
ΔRDW, mean(SD) | 0,53 (1,24) | 0,23 (1,0) | 0,057 | 0,45 (0,6) | 0,43 (1,2) | 0,809 |
- Effects of MTX intake on laboratory parameters at last visit prior to the CV event/last follow up. ΔRDW Change in RDW between initial diagnosis and follow up prior to the CV event/last follow up in patients without CV event. Hb hemoglobin level. In the overall cohort RDW at established disease was not applicable as predictive marker for a CV event. A tendency with lower hemoglobin levels and higher CRP was shown. MTX intake significantly affected RDW